Capivasertib (AZD5363) is an orally active, potent pan-AKT inhibitor (IC50 = 3, 7, and 7 nM for Akt1, Akt2, and Akt3, respectively) that suppresses tumor cell proliferation, particularly in breast cancer and PIK3CA/PTEN-mutated cells. Reagent grade, for research purpose.
Usually ships within 24 hours.